Most people regain a large share of the weight they lost, often around two-thirds within about a year, once they stop a GLP-1 medicine such as semaglutide or tirzepatide. How much comes back varies widely from person to person, and a small minority hold most of their loss or even keep losing. Stopping is not a detox and not a withdrawal syndrome. What the trials describe is the biology of obesity reasserting itself: appetite climbs, fullness fades sooner, and the body burns slightly less energy than before. This page sets out what the trial evidence actually shows, and where it stops short.

• In the STEP 1 extension and SURMOUNT-4 trials, stopping a GLP-1 medicine led to regain of roughly two-thirds of lost weight within a year.
• Individual variation is very wide: some people regain less than a quarter of their loss, while others end heavier than before.
• Weight returns because stopping removes the drug's appetite effect, not because the medicine harms the body. Obesity biology reasserts itself.
• Fat tends to return faster and more completely than muscle, which can worsen body composition after stopping.
• Structured exercise with adequate protein reduces regain better than returning to old habits alone.

Usually some, and often a lot, though rarely all of it within the first year. The clearest evidence comes from two randomised trials. In the STEP 1 extension (semaglutide 2.4 mg once weekly), the subgroup of participants followed off-treatment had lost about 17.3% of body weight by week 68, a figure specific to that extension subgroup rather than the headline STEP 1 result. Over the following year off the drug they regained about two-thirds of that loss, ending roughly 5.6% below their starting weight. Improvements in blood pressure and blood sugar drifted back toward baseline in parallel.

In the SURMOUNT-4 trial (tirzepatide 10 or 15 mg), people who switched to placebo after a 20.9% lead-in loss regained around 14.0% of body weight over the following year, ending about 9.9% below where they started, while those who stayed on treatment held about 25.3%. Regain builds gradually across the year, not overnight.

No, and the spread is one of the most consistent findings. A post-hoc analysis of 308 people in the SURMOUNT-4 placebo arm who had lost at least 10% sorted them by how much they regained by week 88. About 17.5% regained less than a quarter of their loss, a quarter regained 25 to 50%, a third regained 50 to 75%, and 24% regained three-quarters or more. Roughly 1 in 11 ended heavier than they were before starting, while about 4% kept losing weight off the drug while continuing lifestyle measures. Regain is common, but it is not inevitable, and the individual range is very wide.

The weight returns because stopping removes the drug's appetite effect, not because the medicine damages the body. GLP-1 medicines act on the brain to lower hunger and quiet food cravings, and they slow how fast the stomach empties. When the drug clears, usually within two to three weeks for weekly semaglutide or tirzepatide, hunger signals such as ghrelin rise, meals satisfy for less time, and resting energy expenditure stays lower than it was before the weight loss, a pattern called adaptive thermogenesis. A 2026 editorial argues this is better described as disease recurrence than as withdrawal: obesity is a chronic condition, and its biology returns when the treatment is removed. It is not a toxin leaving your system.

Because trials report the same result in more than one way, and each way answers a different question. The two most common estimands used in GLP-1 trials are explained below.

Treatment-regimen: Includes everyone assigned to the drug, including participants who missed doses or stopped treatment early. This approach reflects real-world treatment use. In SURMOUNT-1, tirzepatide 15 mg showed about 20.9% weight loss at 72 weeks.

Efficacy: Estimates the treatment effect assuming participants took the drug exactly as prescribed, representing a best-case scenario. In SURMOUNT-1, tirzepatide 15 mg showed about 22.5% weight loss at 72 weeks.

Both are genuine figures from the same trial. This is why a loose phrase like "up to 21% on GLP-1s" is misleading: it hides which drug, which dose, and which question was being answered.

There is no trial evidence yet that tapering changes how much weight comes back. The major discontinuation studies stopped the drug at a defined visit. None randomly assigned people to taper down versus stop outright and then compared the regain between them. Some pharmacokinetic modelling suggests that spacing doses further apart might retain part of the weight loss with less drug exposure, but modelling is not a head-to-head trial.

Clinicians may still step a dose down for practical reasons such as side effects, tolerance or cost, and doing so under supervision is reasonable. The honest position, as of 2026, is that tapering is clinical convention, not a demonstrated way to prevent regain.

Weight lost on GLP-1 medicines is mostly fat, but some is muscle, and what tends to return is mostly fat. In the STEP 1 DXA substudy, semaglutide 2.4 mg produced about 15% weight loss made up of a 19.3% fall in fat mass and a 27.4% fall in visceral fat, alongside a 9.7% fall in lean mass. Reviews estimate that roughly a third to two-fifths of total weight loss can come from lean tissue, a ratio similar to intensive dieting.

The concern on stopping is that fat is regained faster and more completely than muscle, which can leave a person with more fat and less muscle than before, a state sometimes called sarcopenic obesity. This matters more for older adults and for women with PCOS or thyroid disease, where muscle reserves may already be lower. Direct data on repeated stop-start cycles do not yet exist. This remains a physiological concern rather than a measured trial result.

Structured exercise and continued lifestyle support hold weight better than returning to old habits. In the S-LiTE trial, adults who had lost about 13 kg were assigned to a year of liraglutide, supervised exercise, both, or placebo, then followed for a further year after all treatment stopped.

Supervised Exercise Alone

Weight regained by year 2: About 3.6 kg

Key finding: This group had the least weight regain of the three active arms.

Liraglutide Plus Supervised Exercise

Weight regained by year 2: About 7.1 kg

Key finding: This group had the best body-fat profile at follow-up.

Liraglutide Alone

Weight regained by year 2: About 9.6 kg

Key finding: This group had the most weight regain after the drug was stopped.

Based on the trial evidence, the most effective steps for the period after stopping are:

1. Maintain or start structured aerobic exercise: The S-LiTE trial showed the exercise-only arm regained the least.
2. Add resistance training: Specifically recommended to protect lean mass during and after GLP-1 use.
3. Keep protein intake adequate: Protein is the key dietary lever for preserving muscle through weight change.
4. Stay in clinical contact: Monitor blood pressure, blood sugar and weight so that any drift is caught early.

No trial has yet shown a protocol that reliably locks in the full weight loss after stopping, so partial maintenance through deliberate effort is the realistic goal. As of 2026 there is no Indian cohort or registry describing what discontinuation looks like in Indian adults, so these findings come from largely Western trials and should be read with that caution.

Coming off GLP-1 is a clinical decision, not a solo one.

Because appetite, fullness and energy use all shift when the drug clears, an unplanned stop is exactly where rapid regain tends to happen, along with the drift back of blood pressure and blood sugar. A clinician can help plan a considered off-ramp, protect muscle, and monitor the markers that can slip. Whether to continue, adjust or stop is a decision made with a supervising clinician, not by an app or an article. If it helps to understand how GLP-1 medicines work before that conversation, start there, and bring your questions to a Voy registered clinician.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.